Stocklytics Platform
Asset logo for symbol OCEA
Ocean Biomedical
OCEA47
$0.61arrow_drop_down1.68%-$0.01
Penny Stock
Asset logo for symbol OCEA
OCEA47

$0.61

arrow_drop_down1.68%

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Ocean Biomedical (OCEA) Stocklytics Forecast

Ocean Biomedical, Inc. (OCEA) is a leading biotech company that specializes in the research and development of innovative medical instruments. With a focus on cutting-edge technologies and a commitment to improving patient outcomes, OCEA is poised for significant growth in the coming years.
As for the stock price prediction, it is important to note that predicting the future performance of any stock is inherently uncertain. However, analysts and experts in the field may provide some insights based on their analysis and market trends. OCEA has received positive attention from analysts, with many giving it a favorable rating and predicting a strong future performance.
add Ocean Biomedical to watchlist

Keep an eye on Ocean Biomedical

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Ocean Biomedical (OCEA) stock?

Analysts have set a target price of $15.07 for Ocean Biomedical (OCEA), based on forecasts from 6 analysts. The predicted price range extends from a high of $20 to a low of $10. This represents a potential increase of up to 3.17K% and a decrease of 1.53K% from the current price of $0.61. These forecasts are as of 2023 Mar 13.
help

What are the analyst ratings for Ocean Biomedical (OCEA) stock?

Currently, there are no analyst ratings available for Ocean Biomedical (OCEA), possibly due to insufficient coverage or recent updates.
help

What is the AI price prediction for Ocean Biomedical (OCEA) stock?

At present, there is no AI or machine-learning-based price prediction available for Ocean Biomedical (OCEA) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level